Make your own free website on Tripod.com

 

Addition Of Infliximab To Methotrexate Benefits Patients With Rheumatoid Arthritis

 


WESTPORT, Dec 03 (Reuters Health) - Rheumatoid arthritis patients who do not respond to methotrexate monotherapy improve with the addition of infliximab, an inhibitor of tumor necrosis factor-alpha, researchers report for the ATTRACT Study Group.

 

Dr. Ravinder N. Maini, of Charing Cross Hospital in London, UK, and a multinational team recruited 428 patients with active rheumatoid arthritis who had been taking methotrexate for at least 3 months and had been at a stable dose for at least 4 weeks.

In a double-blind trial, the patients were randomized to receive either a placebo or one of four treatment regimens of infliximab, in addition to a stable dose of methotrexate. The team evaluated the patients every 4 weeks for 30 weeks.

Among patients receiving 3 mg/kg of infliximab, 53% improved at least 20% over baseline if subsequent doses were given every 4 weeks, and 50% improved if later doses were given every 8 weeks.

Among patients receiving 10 mg/kg of infliximab, 58% improved at least 20% over baseline on additional doses every 4 weeks, while 52% improved on doses every 8 weeks. Only 20% of the placebo group improved by 20% over baseline.

The improvements with infliximab were all significantly better than those with placebo, according to the report. The antibody was tolerated well, and adverse events occurred equally often in the placebo and infliximab groups.

Although combination infliximab and methotrexate therapy was proven effective in these patients, "[t]he cost effectiveness of anti-tumour necrosis factor therapy must also await longer term data evaluating the cost of this therapy and the improvement in the quality of life that might follow, set against the cumulative social and healthcare costs of current therapies," the authors write in the December 4th issue of The Lancet.

Lancet 1999;354:1932-1939.

Copyright 1999 Reuters Limited. All rights reserved.

DISCLAIMER:

The materials and information on this server are intended for educational and informational purposes only. The materials and information are not intended to replace the services of a trained health professional or to be a substitute for medical advice of physicians and/or other health care professionals. The International Still's Disease Foundation is not engaged in rendering medical or professional medical services. You should consult your physician on specific medical questions, particularly in matters requiring diagnosis or medical attention. The International Still's Disease Foundation makes no representations or warranties with respect to any treatment, action, application medication or preparation by any person following the information offered or provided within this website.  Any information used from other websites was done so with permission from each site, with an exception to those of "public domain", whereas we believe any site without a cited reference was a "public domain site" and for our use.  The International Still's Disease Foundation is a non-profit organization.   This page was last updated on June 13, 2002

Copyrightę 1999-2002 International Still's Disease Foundation